To compare the effects of losartan and atenolol on plasma fibrinolytic parameters and von Willebrand factor (vWF), Chinese subjects with mild-tomoderate hypertension were randomized to receive losartan (50 mg/day; n = 30) or atenolol (50 mg/day; n = 30) for 8 weeks. If target blood pressure (< 140/90 mmHg) was not achieved at week 4, hydrochlorothiazide (12.5 mg/day) was also administered. Plasma levels of tissue plasminogen activator (tPA), plasminogen activator inhibitor-1 (PAI-1) and vWF were determined at baseline and after treatment. Between-group baseline characteristics and blood pressure decrease were comparable. Losartan significantly reduced plasma PAI-1 and vWF and PAI-1/tPA ratio. Atenolol significantly increased plasma tPA, but PAI-1, vWF and PAI-1/tPA ratio were unchanged. In conclusion, losartan, but not atenolol improved the fibrinolytic system and reduced plasma vWF levels in Chinese hypertensives.
Introduction
Despite having similar blood pressurelowering effects, different classes of antihypertensive drugs do not have the same impact on reducing cardiovascular events in large-scale clinical trials. 1 For example, in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) trial, 2 combined cardiovascular morbidity and mortality was 13% less and the relative risk of stroke was 25% less in the losartan-treated group compared with the atenolol-treated group in hypertensives with left ventricular hypertrophy (LVH) during 5 years of followup. This indicates that other mechanisms beyond their blood pressure-lowering effects might influence the prognosis. Guidelines, such as those published by the Joint National Committee (JNC 7), 3 recommend different indications for the six classes of anti-hypertensive drugs. Cardiovascular events occur frequently in hypertensive patients who also have endothelial cell damage or dysfunction and an impaired fibrinolytic system. 4 Von Willebrand factor (vWF), a specific product of endothelial cells J Liu, N-L Sun, J Yang et al. Effects of losartan on the fibrinolytic system and platelets, is considered a marker of endothelial cell integrity and normal function. 5 The present study was conducted to compare the effects of losartan and atenolol on the fibrinolytic system and vWF activity in Chinese hypertensive patients, and to explore the possible mechanisms of the benefits they confer.
Patients and methods

PATIENTS AND STUDY DESIGN
Chinese subjects with newly diagnosed mildto-moderate hypertension, whose systolic blood pressure (SBP) was 140 -179 mmHg, and/or diastolic blood pressure (DBP) was 90 -109 mmHg, according to 1999 World Health Organization (WHO)/International Society of Hypertension (ISH) Guidelines, 6 were included in this study. Exclusion criteria were: coronary heart disease; cerebrovascular disease; diabetes and other endocrine or metabolic diseases; liver and renal disease; secondary hypertension; and sinus bradycardia. The study was conducted according to the Helsinki Declaration and the study protocol was approved by the Ethics Committee of Peking University People's Hospital (Beijing, China). All patients gave their written informed consent.
Patients were divided randomly and equally into two treatment groups: losartan (50 mg/day), and atenolol (50 mg/day). If target blood pressure (< 140/90 mmHg) in individual patients in either group was not achieved by week 4, hydrochlorothiazide (12.5 mg/day) was added to the antihypertensive treatment regimen. All subjects were treated and followed-up for 8 weeks.
DATA COLLECTION
Baseline and follow-up blood pressures were measured between 08:00 and 10:00 h (before medication) in triplicate using Korotkoff's sounds with a stethoscope and a mercury sphygmomanometer after subjects had remained quiet for 15 min in a seated position.
Following an 8-h fasting period, blood (5 ml from each patient) was drawn in the early morning at baseline and again 8 weeks after treatment, with minimal trauma to the antecubital vein. Samples were centrifuged at 3000 rpm for 20 min within 30 min of collection, and the citrated plasma stored at -80°C until analysis.
Plasma levels of vWF, tissue plasminogen activator (tPA) and plasminogen activator inhibitor-1 (PAI-1) in the two groups were examined at baseline and 8 weeks after therapy. The vWF was measured by immune turbidimetry. 7 The tPA and PAI-1 levels were detected using an enzyme-linked immunosorbent assay (ELISA), 8 and the PAI-1/tPA ratio was calculated.
STATISTICAL ANALYSIS
Power calculation was based on the levels of vWF, a marker of endothelial damage/ dysfunction.
Our previous study (unpublished) showed a SD of vWF of 37.4% in subjects with hypertension, hence we assumed that about a 30% mean difference of vWF would be observed between the two treatment groups. With 80% power at the 5% significance level, each group would require at least 24 subjects. Data collection and analysis were undertaken using SPSS ® version 11.5 (SPSS Inc, Chiocago, IL, USA). Within-group comparisons of blood pressure before treatment and at weeks 4 and 8 and comparisons of tPA, PAI-1, PAI-1/tPA ratio and vWF before and after treatment were analysed with a paired t-test. Between-group comparisons of these variables were performed by an independent sample t-test. A P-value < 0.05 was considered statistically significant.
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Results
A total of 60 Chinese subjects newly diagnosed with mild to moderate hypertension participated in the study: 50 mg/day losartan group (n = 30; mean age 52.1 years); 50 mg/day atenolol group (n = 30; mean age 52.2 years). All baseline data were comparable between the two groups ( Table 1) .
Mean SBP/DBP decreased significantly in both groups after treatment: 136.8/87.2 mmHg (losartan) versus 137.7/88.2 mmHg (atenolol); P < 0.01 for both groups at week 4 compared with baseline, but there was no significant difference between the two groups. Eight patients given losartan and nine given atenolol failed to reach the target blood pressure (< 140/90 mmHg) at week 4, so received hydrochlorothiazide according the study protocol for an additional 4 weeks. At week 8, mean blood pressure was significantly lower than baseline in both groups (P < 0.01) ( Table 2 ). There was no significant difference in mean blood pressure between the two groups at week 8. In three patients in each group (total six patients), blood pressure did not reach the target of < 140/90 mmHg after 8 weeks' treatment.
Heart rate did not change significantly in the losartan group after 4 and 8 weeks, however, a significant decrease occurred in the atenolol group at weeks 4 and 8 (67.4 ± 5.6 beats/min and 64.4 ± 5.5 beats/min, respectively; P < 0.01 compared with baseline) ( Table 2) .
No severe adverse events were seen in the two groups. The most frequent side-effects were dizziness (five cases in the losartan group), palpitations and fatigue (six cases in the atenolol group, with no ectopic rhythm on electrocardiography, heart rate at 52 -66 beats/min). None of the side-effects disrupted therapy.
The baseline levels of the fibrinolytic system indices and vWF were comparable between the two groups (Table 2 ). In the losartan group, the mean plasma tPA level did not change from baseline to week 8 of 1.5 ± 0.9 1.5 ± 1.0 LDL-cholesterol (mmol/l) 3.0 ± 0.8 3.0 ± 1.1 HDL-cholesterol (mmol/l) 1.1 ± 0.3 1.2 ± 0.5
Values are mean ± SD or n. All data are not statistically significant (P > 0.05) between groups. LDL, low density lipoprotein; HDL, high density lipoprotein.
J Liu, N-L Sun, J Yang et al. Effects of losartan on the fibrinolytic system treatment, whereas the mean PAI-1 level and the PAI-1/tPA ratio were significantly decreased after 8 weeks of losartan treatment compared with baseline (P < 0.05 for both comparisons). In the atenolol group, the mean plasma tPA level significantly increased after 8 weeks compared with baseline (P < 0.05), but mean plasma PAI-1 and the PAI-1/tPA ratio were not significantly changed. There was a trend towards a lower PAI-1 level in the losartan group compared with the atenolol group at week 8, but this was not significant.
The mean plasma vWF level was significantly reduced after 8 weeks of losartan treatment compared with baseline (P < 0.01), but remained unchanged for atenolol (Table 2) ; there was a significant between-group difference at week 8 (P < 0.01).
Discussion
The present study showed that both losartan and atenolol effectively reduced blood pressure in Chinese patients with mild-tomoderate hypertension during 8 weeks of therapy. In addition, losartan significantly decreased plasma levels of vWF and PAI-1, improving the fibrinolytic status, but did not influence the level of tPA. Atenolol increased plasma levels of tPA but had no effect on vWF and PAI-1 levels.
Endothelial cells and platelets secrete vWF, which is an adhesion molecule and regarded as one of the markers of endothelium dysfunction or damage. 5 It plays a key role in the process of platelet adhesion and aggregation and is elevated in hypertensive patients with target organ damage, such as LVH, ischaemic heart disease and stroke. 9 Increased activity or antigen concentrations of PAI-1 represent decreased fibrinolytic function and increased activity of tPA reflects higher fibrinolytic activity; 10,11 hence tPA and PAI-1 play crucial roles in regulating the fibrinolytic function and can be used as measures of fibrinolytic function. The risk of thrombosis increases when the dynamic balance between tPA and PAI-1 is disrupted. Different forms of tPA antigen exist in blood, including a free active form and a bound J Liu, N-L Sun, J Yang et al.
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form that is combined with PAI-1 or other inhibitors in the blood. 11 Free tPA is cleared more rapidly than the tPA/PAI-1 complex, so measurement of plasma tPA antigen relates to levels of the tPA/PAI-1 complex and can be used as an alternative indicator of high PAI-1 activity. 11 It has become increasingly evident that, despite their similar blood pressure-lowering effects, some anti-hypertensive agents possess other properties and, hence, are not the same in reducing cardiovascular events, such as death, myocardial infarction and stroke in hypertensive patients, that might contribute significantly to the prognosis of hypertensive patients. For example, in the LIFE trial, 2 losartan further reduced the relative risk of combined cardiovascular endpoints to 13% and risk of stroke to 25%, despite having similar anti-hypertensive effects to atenolol. The exact mechanism by which these additional benefits occurred remains unclear.
The renin-angiotensin system (RAS) plays a key role in the process of hypertension. Angiotensin II, which is the most important effector peptide of the RAS, can stimulate the generation of PAI-1 directly or indirectly, and angiotensin-converting enzyme (ACE) inhibitor can decrease PAI-1 and increase the activity of the fibrinolytic system, although inconsistent conclusions have been drawn from various trials. 12, 13 The present study demonstrated that PAI-1 and fibrinolytic parameters were significantly decreased in essential hypertensive patients treated with losartan, indicating a beneficial effect on the fibrinolytic system, as well anti-hypertensive effects. In addition, losartan significantly decreased plasma vWF levels, suggesting improved endothelial function.
Atenolol, a β-receptor blocker that is widely used in China and worldwide, combines stable efficacy with low price and convenience for community-based use. It was once very central to China's hypertension control strategy under medical treatment insurance. However, compared with other active anti-hypertensive drugs, atenolol has been shown to be inferior in reducing cardio-cerebrovascular events, especially stroke. 14 In the present study, atenolol effectively decreased blood pressure, but was not beneficial to fibrinolytic activity and vWF. In contrast to losartan, atenolol significantly enhanced the expression of tPA, which might have an adverse impact on fibrinolytic activity. These effects might be one of the possible mechanisms for the more positive effect of losartan on stroke risk than atenolol, as observed in the LIFE trial. 2 A range of mechanisms rather than a single action might be involved in the stroke protective effects of losartan, such as benefits on LVH regression, atrial fibrillation, thrombus formation/platelet aggregation, serum uric acid, albuminuria, new onset diabetes, vascular structure and central pulse pressure. 15 Clearly, further longer term follow-up studies are required to elucidate the effects of losartan and atenolol on fibrinolytic parameters and other factors, and whether there is any association between these factors and the risk of major cardiovascular events in patients with hypertension.
